Around 1969, mestranol was replaced by ethinylestradiol in most or all combined oral contraceptives due to widespread panic about the recently uncovered increased risk of [[venous thromboembolism]] with estrogen-containing oral contraceptives.<ref name="Aronson2009">{{cite book|author=Jeffrey K. Aronson|title=Meyler's Side Effects of Endocrine and Metabolic Drugs|url=https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA224|date=21 February 2009|publisher=Elsevier|isbn=978-0-08-093292-7|pages=224â€“}}</ref> The rationale was that ethinylestradiol was approximately twice as potent by weight as mestranol and hence that the dose could be halved, which it was thought might result in a lower incidence of venous thromboembolism.<ref name="Aronson2009" /> Whether this actually did result in a lower incidence of venous thromboembolism has never been assessed.<ref name="Aronson2009" />
